シスタチンC測定市場：製品タイプ、測定法、サンプルタイプ、設定、用途、エンドユーザー別-2024-2030年世界予測

シスタチンC測定市場規模は、2023年に4億2,747万米ドルと推定され、2024年には4億5,983万米ドルに達し、CAGR 7.24%で2030年には6億9,741万米ドルに達すると予測されています。

シスタチンC測定は、体内のほぼすべての細胞で産生されるタンパク質であるシスタチンCのレベルを測定するために利用される臨床検査です。クレアチニン測定が誤解を招くような例外的な場合に最も有用です。腎臓病の有病率の増加と老年人口の増加が、シスタチンC測定の必要性を高めています。さらに、高度な自動検査法のイントロダクションより、シスタチンCの入手可能性が高まり、臨床的に採用されるようになったことが、市場の成長につながった。対照的に、シスタチンC測定は製造コストが高く、解釈のガイドラインが厳しいため、その採用が制限されています。しかし、いくつかのベンダーはこの問題を克服するために研究開発に投資しています。さらに、診断技術の進歩、新たな調査、シスタチンC測定に関する臨床ガイドラインの継続的な発行が、大きな市場成長機会をもたらしています。

製品診断と病態モニタリングのための消費者嗜好のシスタチンC分析装置

シスタチンC分析装置は、シスタチンc濃度を測定するための医療機器です。この装置は、腎臓病などの診断やモニタリングに不可欠です。シスタチンCキットは、細胞培養上清、血清、血漿、唾液、尿、およびヒト乳汁中のヒトシスタチンcを正確に測定するように設計されています。シスタチンC試薬は、正確で精密な結果をもたらす最高品質の試薬として認められています。これは、サンプル中のシスタチンC濃度を測定するために実験室で使用される化学物質です。幅広いメソッドとフォーマットにより、どのような規模の検査室にも高い柔軟性と選択肢を提供します。

方法酵素結合免疫吸着測定法（ELISA）の利用拡大シスタチンC測定

酵素結合免疫吸着測定法（ELISA）は、抗体を用いてサンプル中のシスタチンc濃度を検出・定量する方法です。ELISA法はその感度と特異性で知られており、腎機能のマーカーとしてシスタチンC値を評価するために臨床検査室で広く用いられている方法です。シスタチンCの化学発光免疫測定法は、高い感度と広いダイナミックレンジを提供し、多くの場合自動化されているため、効率的なハイスループット検査が可能です。シスタチンCレベルの定量における精度と正確性から、臨床検査室で一般的に使用されています。免疫蛍光法はシスタチンC抗体を標識するために蛍光色素またはタンパク質を利用し、蛍光は顕微鏡または特殊な装置で検出されます。シスタチンCの存在を視覚的に確認する必要がある研究環境や特定の臨床場面で有用です。粒子増強ネフェロメトリック免疫測定法（PENIA）は、感度と精度が高く、低濃度サンプルに適しており、シスタチンCの定量における精度と信頼性、特に腎機能評価において臨床検査室で広く使用されています。粒子増強比濁免疫測定法（PETIA）は、シスタチンCの存在下での抗原抗体複合体形成による濁りの程度を測定するもので、簡便で費用対効果が高く、日常臨床での使用に適しており、特に大規模検査においてシスタチンC濃度の定量に臨床検査室で一般的に使用されています。

設定ポイントオブケアにおけるシスタチンC測定の利用拡大

検査室環境では、シスタチンC測定は専門的な機器と訓練を受けたスタッフを備えた臨床検査室で実施されます。患者から血液サンプルを採取し、高度な検査機器を用いて処理し、シスタチンCの濃度を測定します。このような環境では、綿密な分析と正確な測定が可能であり、多くの場合、より広範な検査と高いスループットが提供されますが、ポイントオブケア環境と比較して結果が出るまでに時間がかかる場合があります。ポイントオブケア設定では、シスタチンC測定は診療所、医院、病院のベッドサイドなど、患者のいる場所またはその近くで実施されます。シスタチンCのポイントオブケア検査は、ヘルスケア提供者が即座に臨床判断を下せるよう、迅速な結果を提供するように設計されています。これらの検査は多くの場合、より簡便で迅速であり、必要な機器や専門的なトレーニングは最小限です。これらの検査は、迅速な評価や、迅速な結果が即座の治療決定に不可欠な状況に有益です。

サンプルの種類サンプル中のクレアチニン量を測定するシスタチンC測定の重要な役割の尿サンプル

シスタチンC測定では血液サンプル、特に血清と血漿を採用しています。これらの検体は腎機能のバイオマーカーとしてシスタチンC値を評価するために不可欠です。血液検体は、臨床医に慢性腎臓病を含む病態の診断やモニタリングのための貴重な情報を提供し、腎臓の健康状態やプロセスに関する洞察を提供します。シスタチンC測定のための尿検体では、尿中のシスタチンC濃度を測定します。尿中のシスタチンCは尿細管機能障害やその他の腎臓の問題を示します。シスタチンCの測定法として血液と尿のどちらを選択するかは、個々の患者のニーズや状況に依存することが多いです。これらの方法は、より伝統的なアプローチを提供する血液アッセイと、血液サンプリングが不可能な場合に実行可能な代替法を提供する尿アッセイにより、貴重な診断的洞察を提供します。

応用腎機能診断へのシスタチンC測定の応用の拡大

診断用として、シスタチンC測定は腎機能の評価に不可欠であり、腎疾患の早期発見とモニタリングを可能にします。臨床現場では、鑑別診断、リスク層別化、個別化ヘルスケアに使用されています。研究開発において、シスタチンC測定は腎臓の機能や病気を理解するためのバイオマーカー探索に不可欠です。腎臓の健康に対する介入の影響を評価するための臨床試験や研究に応用され、腎臓研究の進歩に貢献する疾患メカニズムの探求をサポートします。

エンドユーザー学術研究センターでのバイオマーカー調査におけるシスタチンC測定の利用拡大

学術研究センターでは、腎機能や疾患の調査にシスタチンC測定を利用することが多くあります。これには、早期発見のためのバイオマーカーの研究、腎疾患の進行の理解、潜在的な治療法の有効性の評価などが含まれます。学術研究者は、腎機能や疾患の新規指標を同定するバイオマーカー探索プロジェクトにシスタチンC測定を使用することができます。診断ラボでは、包括的な腎機能検査パネルの一部としてシスタチンC測定を日常的に採用しています。これは腎機能障害の早期発見に役立ち、臨床医に患者管理のための貴重な情報を提供します。慢性腎臓病の場合、診断検査室は患者の継続的なモニタリングにシスタチンC測定を利用します。定期的な検査により、腎機能の変化を追跡し、治療計画をタイムリーに調整することができます。病院やクリニックでは、シスタチンC測定は医療従事者が腎臓機能に関する臨床判断を下す際に役立ちます。高値の場合、さらなる調査や患者ケアの調整が必要となります。学術研究センターでは、科学的知識を深めることを目的としてシスタチンC測定を使用し、診断研究所では、日常的な腎機能検査や鑑別診断に使用しています。病院やクリニックでは、シスタチンC測定を臨床的な意思決定や腎臓疾患患者の管理に使用しています。

地域別インサイト

北米、特に米国では、大手ヘルスケア・診断企業、研究機関、確立された医療インフラが存在し、シスタチンC測定市場に大きく貢献しています。さらに、米国食品医薬品局（FDA）やカナダ保健省（Health Canada）などの政府規制機関による厳格な規制基準が、シスタチンC測定の製品承認に重要な役割を果たしています。南米では、病気の早期診断の重要性に対する認識が高まり、ヘルスケア部門が成長していることが、シスタチンC測定のニーズ拡大に寄与していると予想されます。欧州では、ドイツ、フランス、スイス、英国などの国々が、医療インフラが確立され、高額な支出を行い、医薬品やバイオテクノロジー分野の技術進歩に注力しているため、シスタチンC測定の採用拡大に貢献しています。中東・アフリカでは、人口の増加に伴う慢性疾患の蔓延の増加や、ヘルスケア部門への多額の投資による診断能力の向上が、同地域でのシスタチンC測定の利用を促進すると予想されます。中国や日本を含むAPAC諸国では、老年人口の増加と慢性疾患の有病率の上昇が市場の拡大に寄与しています。中国、インド、オーストラリアなどの国々では、腎臓病に対する意識の高まりや、政府や地域のヘルスケア企業による積極的な健康診断の取り組みが、シスタチンC測定のような診断検査の必要性を高めています。インドネシア、タイ、ベトナムなどの新興国では、経済発展、医療アクセスの拡大、予防医療の重視がシスタチンC測定の適用を後押ししています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはシスタチンC測定市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、シスタチンC測定市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.シスタチンC測定市場の市場規模および予測は？

2.シスタチンC測定市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.シスタチンC測定市場の技術動向と規制枠組みは？

4.シスタチンC測定市場における主要ベンダーの市場シェアは？

5.シスタチンC測定市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 腎臓疾患の罹患率の上昇と高齢者人口の増加
    • 腎疾患のヘルスケアインフラへの積極的な投資
  • 抑制要因
    • シスタチンCアッセイの開発コストの高さと製品リコールの発生率
  • 機会
    • シスタチンC測定テストの進歩
    • クレアチニンベースの検査の代替としてシスタチンC検査を採用するための新たな調査
  • 課題
    • 熟練した研究室専門家の不足とシスタチンC測定に関連する技術的な課題
• 市場セグメンテーション分析
  • 製品：診断および状態監視用の消費者好みのシスタチンC分析装置
  • 方法：シスタチンCアッセイにおける酵素結合免疫吸着測定法（ELISA）の利用拡大
  • 設定：シスタチンCアッセイのポイントオブケア設定の使用拡大
  • サンプルタイプ：サンプル中のクレアチニンの量を測定するためのシスタチンC測定の重要な役割の尿サンプル
  • 応用：腎機能診断におけるシスタチンCアッセイの応用拡大
  • エンドユーザー：バイオマーカー研究のための学術研究センターにおけるシスタチンCアッセイの利用拡大
• 市場動向分析
  • 確立されたヘルスケアインフラと、南北アメリカにおけるシスタチンC測定ソリューションの商業化への重点
  • アジア太平洋地域における腎疾患の負担を軽減するための政府支援プログラム
  • EMEA地域における新しいシスタチンCアッセイ製品の開発と拡大に注力
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 シスタチンC測定市場：製品別

• アナライザ
• キット
• 試薬

第7章 シスタチンC測定市場：方法別

• 化学発光免疫測定法
• 酵素免疫測定法
• 免疫蛍光アッセイ
• 粒子増強比濁免疫測定法
• 粒子増強比濁免疫測定法

第8章 シスタチンC測定市場サンプルタイプ別

• 血
• 尿

第9章 シスタチンC測定市場設定することにより

• 実験室の設定
• ポイントオブケア設定

第10章 シスタチンC測定市場：用途別

• 診断の使用
• 研究開発

第11章 シスタチンC測定市場：エンドユーザー別

• 学術研究センター
• 診断検査室
• 病院・クリニック

第12章 南北アメリカのシスタチンC測定市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のシスタチンC測定市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのシスタチンC測定市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • ジャナ・ケア、自己採血検査の商業化に向けて600万米ドルを調達
  • ロードスメッド、マハラシュトラ州初の病理学センター開設を発表
  • Renalyse、GENESIS Venturesの参加を得て100万ユーロの資金調達ラウンドを完了
  • Renalytix社、2型糖尿病患者の腎臓病の早期予後検出のためのKidneyIntelXの商業化拡大にEVERSANA社を選択
  • eGFRの新しい欧州シスタチンC式はより正確になる可能性がある
  • ジャナ・ケア、ロシュと提携し、慢性腎臓病および心臓病患者の遠隔ケア改善に向けた血液検査プラットフォームの開発と配布を開始
  • ゲンティアン・ダイアグノスティクス ASAがシスタチンCの販売契約を締結
  • ブルーム・ダイアグノスティクス、新たな腎臓検査を発表

第16章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. CYSTATIN C ASSAY MARKET RESEARCH PROCESS
• FIGURE 2. CYSTATIN C ASSAY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CYSTATIN C ASSAY MARKET SIZE, 2018-2030 (USD THOUSAND)
• FIGURE 4. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 6. CYSTATIN C ASSAY MARKET DYNAMICS
• FIGURE 7. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 9. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 11. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 13. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 15. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 17. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 18. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 19. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 21. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 22. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 23. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 27. CYSTATIN C ASSAY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 28. CYSTATIN C ASSAY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CYSTATIN C ASSAY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CYSTATIN C ASSAY MARKET SIZE, 2018-2023 (USD THOUSAND)
• TABLE 4. GLOBAL CYSTATIN C ASSAY MARKET SIZE, 2024-2030 (USD THOUSAND)
• TABLE 5. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 6. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 7. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 8. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 9. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY ANALYZER, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 10. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY ANALYZER, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 11. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY KITS, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 12. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY KITS, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 13. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 14. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 15. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 16. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 17. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 18. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 19. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 20. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 21. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 22. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 23. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 24. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 25. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 26. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 27. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 28. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 29. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY BLOOD, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 30. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY BLOOD, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 31. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY URINE, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 32. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY URINE, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 33. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 34. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 35. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY LABORATORY SETTING, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 36. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY LABORATORY SETTING, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 37. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY POINT OF CARE SETTING, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 38. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY POINT OF CARE SETTING, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 39. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 40. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 41. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY DIAGNOSIS USE, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 42. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY DIAGNOSIS USE, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 43. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 44. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 45. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 46. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 47. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 48. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 49. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 50. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 51. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD THOUSAND)
• TABLE 52. GLOBAL CYSTATIN C ASSAY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD THOUSAND)
• TABLE 53. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 54. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 55. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 56. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 57. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 58. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 59. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 60. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 61. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 62. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 63. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 64. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 65. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
• TABLE 66. AMERICAS CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
• TABLE 67. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 68. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 69. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 70. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 71. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 72. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 73. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 74. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 75. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 76. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 77. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 78. ARGENTINA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 79. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 80. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 81. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 82. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 83. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 84. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 85. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 86. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 87. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 88. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 89. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 90. BRAZIL CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 91. CANADA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 92. CANADA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 93. CANADA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 94. CANADA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 95. CANADA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 96. CANADA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 97. CANADA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 98. CANADA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 99. CANADA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 100. CANADA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 101. CANADA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 102. CANADA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 103. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 104. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 105. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 106. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 107. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 108. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 109. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 110. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 111. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 112. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 113. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 114. MEXICO CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 115. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 116. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 117. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 118. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 119. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 120. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 121. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 122. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 123. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 124. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 125. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 126. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 127. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY STATE, 2018-2023 (USD THOUSAND)
• TABLE 128. UNITED STATES CYSTATIN C ASSAY MARKET SIZE, BY STATE, 2024-2030 (USD THOUSAND)
• TABLE 129. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 130. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 131. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 132. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 133. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 134. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 135. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 136. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 137. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 138. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 139. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 140. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 141. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
• TABLE 142. ASIA-PACIFIC CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
• TABLE 143. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 144. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 145. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 146. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 147. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 148. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 149. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 150. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 151. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 152. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 153. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 154. AUSTRALIA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 155. CHINA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 156. CHINA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 157. CHINA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 158. CHINA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 159. CHINA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 160. CHINA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 161. CHINA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 162. CHINA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 163. CHINA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 164. CHINA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 165. CHINA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 166. CHINA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 167. INDIA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 168. INDIA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 169. INDIA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 170. INDIA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 171. INDIA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 172. INDIA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 173. INDIA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 174. INDIA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 175. INDIA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 176. INDIA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 177. INDIA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 178. INDIA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 179. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 180. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 181. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 182. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 183. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 184. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 185. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 186. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 187. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 188. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 189. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 190. INDONESIA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 191. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 192. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 193. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 194. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 195. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 196. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 197. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 198. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 199. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 200. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 201. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 202. JAPAN CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 203. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 204. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 205. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 206. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 207. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 208. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 209. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 210. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 211. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 212. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 213. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 214. MALAYSIA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 215. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 216. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 217. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 218. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 219. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 220. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 221. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 222. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 223. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 224. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 225. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 226. PHILIPPINES CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 227. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 228. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 229. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 230. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 231. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 232. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 233. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 234. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 235. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 236. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 237. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 238. SINGAPORE CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 239. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 240. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 241. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 242. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 243. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 244. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 245. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 246. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 247. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 248. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 249. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 250. SOUTH KOREA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 251. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 252. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 253. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 254. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 255. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 256. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 257. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 258. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 259. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 260. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 261. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 262. TAIWAN CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 263. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 264. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 265. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 266. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 267. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 268. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 269. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 270. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 271. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 272. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 273. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 274. THAILAND CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 275. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 276. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 277. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 278. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 279. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 280. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 281. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 282. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 283. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 284. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 285. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 286. VIETNAM CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 292. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA CYSTATIN C ASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
• TABLE 301. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 302. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 303. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 304. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 305. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 306. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 307. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 308. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 309. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 310. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 311. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 312. DENMARK CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 313. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 314. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 315. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 316. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 317. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 318. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 319. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 320. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 321. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 322. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 323. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 324. EGYPT CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 325. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 326. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 327. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 328. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 329. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 330. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 331. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 332. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 333. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 334. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 335. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 336. FINLAND CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 337. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 338. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 339. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 340. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 341. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 342. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 343. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 344. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 345. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 346. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 347. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 348. FRANCE CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 349. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 350. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 351. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 352. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2024-2030 (USD THOUSAND)
• TABLE 353. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD THOUSAND)
• TABLE 354. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD THOUSAND)
• TABLE 355. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2018-2023 (USD THOUSAND)
• TABLE 356. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY SETTING, 2024-2030 (USD THOUSAND)
• TABLE 357. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2018-2023 (USD THOUSAND)
• TABLE 358. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY APPLICATION, 2024-2030 (USD THOUSAND)
• TABLE 359. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2018-2023 (USD THOUSAND)
• TABLE 360. GERMANY CYSTATIN C ASSAY MARKET SIZE, BY END-USER, 2024-2030 (USD THOUSAND)
• TABLE 361. ISRAEL CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
• TABLE 362. ISRAEL CYSTATIN C ASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
• TABLE 363. ISRAEL CYSTATIN C ASSAY MARKET SIZE, BY METHOD, 2018-2023 (USD THOUSAND)
• TABLE 364. ISRAEL CYSTATIN C ASSAY

[194 Pages Report] The Cystatin C Assay Market size was estimated at USD 427.47 million in 2023 and expected to reach USD 459.83 million in 2024, at a CAGR 7.24% to reach USD 697.41 million by 2030.

The cystatin C assay is a laboratory test utilized to measure the levels of cystatin C, a protein produced by nearly all cells in the body. It is most useful in exceptional cases where creatinine measurement could be misleading. The increasing prevalence of kidney diseases and the growing geriatric population drive the need for cystatin C assay. Furthermore, the increasing availability and clinical adoption of cystatin C with the introduction of advanced automated testing methods have led to its market growth. In contrast, the high manufacturing costs of cystatin C assays and strict interpretation guidelines restrict their adoption. However, several vendors are investing in R&D to overcome its issues. Furthermore, advancements in diagnostics technologies, emerging research, and ongoing publishing of clinical guidelines for cystatin C assay provide substantial market growth opportunities.

Product: Consumer preference cystatin C analyzer for diagnosis and monitoring conditions

A cystatin C analyzer is a medical device used to measure cystatin c concentration. This device is crucial for diagnosing and monitoring conditions such as kidney disease. Cystatin C kits are designed to accurately measure human cystatin c in cell culture supernatants, serum, plasma, saliva, urine, and human milk. Cystatin C reagents are recognized as being of the highest quality, producing accurate and precise results. It is a chemical substance used in the laboratory to measure cystatin C levels in the sample. A wide range of methods and formats provide greater flexibility and choice for any laboratory size.

Method: Expanding usage of enzyme-linked immunosorbent assay (ELISA) for cystatin C assays

The enzyme-linked immunosorbent assay (ELISA) method involves using antibodies using antibodies to detect and quantify the cystatin c levels in a sample. ELISA is known for its sensitivity and specificity, making it a widely used method in clinical laboratories for assessing cystatin C levels as a marker for renal function. A chemiluminescent immunoassay for cystatin C offers high sensitivity and wide dynamic range and is often automated, enabling efficient high-throughput testing. It is commonly used in clinical laboratories for its precision and accuracy in quantifying cystatin C levels. Immunofluorescence assay utilizes fluorescent dyes or proteins to label cystatin C antibodies, and fluorescence is detected under a microscope or specialized instrument. It is useful in research settings and specific clinical scenarios requiring visual confirmation of cystatin C presence. Particle-enhanced nephelometric immunoassay (PENIA) offers high sensitivity and precision, is suitable for low-concentration samples, and is widely used in clinical laboratories for its accuracy and reliability in quantifying cystatin C, especially in renal function assessment. Particle-enhanced turbidimetric immunoassay (PETIA) measures the degree of turbidity caused by the formation of antigen-antibody complexes in the presence of cystatin C. It is simple, cost-effective, suitable for routine clinical use, and commonly employed in clinical laboratories to quantify cystatin C levels, especially in large-scale testing.

Setting: Expanding usage of point-of-care setting for cystatin C assays

In a laboratory setting, cystatin C assay is performed in clinical laboratories equipped with specialized equipment and trained personnel. Blood samples are collected from patients and then processed using advanced laboratory instruments to measure the levels of cystatin C. This setting allows for meticulous analysis and precise measurements, often offering a wider range of tests and higher throughput, although it might take longer to generate results compared to point-of-care settings. In a point-of-care setting, the cystatin C assay is conducted at or near the patient's location, such as within a clinic, doctor's office, or at the bedside in a hospital. Point-of-care tests for cystatin C are designed to provide rapid results, allowing healthcare providers to make immediate clinical decisions. These tests are often simpler, quicker, and require minimal equipment or specialized training. They are beneficial for quick assessments or situations where rapid results are crucial for immediate treatment decisions.

Sample Type: Significant role urine sample for cystatin C assay for measuring the amount of creatinine in a sample

The cystatin C assay employs blood samples, specifically serum and plasma. These samples are vital for evaluating cystatin C levels as a biomarker for kidney function. Blood samples provide clinicians with valuable information to diagnose and monitor conditions, including chronic kidney disease, offering insights into renal health and processes. Urine samples for cystatin c assay involve measuring the concentration of cystatin c in the urine. Cystatin C in urine indicates tubular dysfunction and other renal issues.The choice between blood and urine assays for cystatin C often relies on individual patient needs and circumstances. These methods provide valuable diagnostic insight, with blood assays offering a more traditional approach and urine assays providing a viable alternative when blood sampling is untenable.

Application: Increasing application of cystatin C assays for diagnosis of renal function

For diagnostic use, cystatin C assays are vital for assessing renal function, enabling early detection and monitoring of kidney diseases. It is used in differential diagnosis, risk stratification, and personalized healthcare in clinical settings. For research & development, cystatin C assays are integral in biomarker discovery for understanding kidney function and diseases. It is applied in clinical trials and studies to evaluate the impact of interventions on kidney health, and supports the exploration of disease mechanisms, contributing to advancements in renal research.

End-user: Expanding usage of cystatin C assays in academic research centers for studying biomarkers

Academic research centers often utilize cystatin C assays to investigate kidney function and diseases. This includes studying biomarkers for early detection, understanding the progression of renal disorders, and assessing the effectiveness of potential treatments. Academic researchers can use cystatin C assays in biomarker discovery projects to identify novel indicators of kidney function or diseases. Diagnostic laboratories routinely employ cystatin C assays as part of comprehensive renal function testing panels. This helps in the early detection of kidney dysfunction and provides clinicians with valuable information for patient management. In cases of chronic kidney diseases, diagnostic laboratories utilize cystatin C assays for ongoing monitoring of patients. Regular testing helps track changes in kidney function and allows for timely adjustments to treatment plans. In hospitals and clinics, cystatin C assays aid healthcare professionals in making clinical decisions related to kidney function. Elevated levels may prompt further investigation or adjustments in patient care. The objective of academic research centers to use cystatin C assays is to focus on advancing scientific knowledge, while diagnostic laboratories use it for routine kidney function testing and differential diagnosis. Hospitals & clinics use cystatin C assays for clinical decision-making and management of patients with kidney disorders.

Regional Insights

In North America, particularly in the U.S., the presence of major healthcare and diagnostic companies, research institutions, and well-established healthcare infrastructure is a significant contributor to the cystatin C assay market. Moreover, stringent regulatory standards laid by government regulatory agencies, including the U.S. Food and Drug Administration (FDA) and Health Canada, play a crucial role in product approvals for cystatin c assay. In South America, increasing awareness about the importance of early disease diagnosis and a growing healthcare sector is expected to contribute to the expanding need for cystatin C assay. In Europe, countries such as Germany, France, Switzerland, and the United Kingdom are contributing to the growing adoption of cystatin C assay as they have well-established healthcare infrastructure with high spending and a focus on technological advancements in the pharmaceutical and biotechnology sectors. In the Middle East and Africa, the growing prevalence of chronic diseases with increasing population and a focus on improving diagnostic capabilities with investing heavily in the healthcare sector is expected to bolster the usage of cystatin C assay in the region. In APAC countries, including China and Japan, the increasing number of geriatric residents and the rising prevalence of chronic diseases contribute to the expansion of the market. In countries including China, India, and Australia, increasing awareness of kidney diseases and proactive health screening initiatives by government and regional healthcare companies increase the need for diagnostic tests such as cystatin c assay. In emerging nations such as Indonesia, Thailand, and Vietnam, economic development, expanding healthcare access, and an emphasis on preventive healthcare support the application of cystatin C assay in the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cystatin C Assay Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cystatin C Assay Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cystatin C Assay Market, highlighting leading vendors and their innovative profiles. These include Abbexa Limited, Abbott Laboratories, Abcam PLC, Advy Chemical Pvt. Ltd., Agilent Technologies, Inc., AOBIOUS Inc., Arbor Assays Inc., Aviva Systems Biology Corporation, BBI Solutions OEM Limited, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biorbyt Ltd, BioVendor - Laboratorni medicina a.s., Boditech Med Inc., Cepham Life Sciences, Inc., Cusabio Technology LLC, DIALAB GmbH, DiaSys Diagnostic Systems GmbH, Diazyme Laboratories, Inc. by General Atomics, Eagle Biosciences, Inc., Elabscience Biotechnology Inc., Ethos Biosciences, Inc., Eurolyser Diagnostica GmbH by Mars, Incorporated, F. Hoffmann-La Roche Ltd, Fapon Biotech Inc., Fortress Diagnostics Ltd., Gentian Diagnostics ASA, Getein Biotech, Inc., ImmunoDiagnostics Limited, Kamiya Biomedical Company, Laboratory Corporation of America Holdings, Merck KGaA, Proteintech Group, Inc., PZ CORMAY S.A., Randox Laboratories Ltd., RayBiotech, Inc., Sekisui Diagnostics, LLC, Siemens Healthineers AG, Sino Biological, Inc., Thermo Fisher Scientific Inc., Tosoh Corporation, Weldon Biotech, and Zhejiang Kangte Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Cystatin C Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Analyzer
  • Kits
  • Reagents

• Method
  • Chemiluminescence Immunoassay
  • Enzyme linked Immunosorbent Assay
  • Immunofluorescence Assay
  • Particle-enhanced Nephelometric Immunoassay
  • Particle-enhanced Turbidimetric Immunoassay

• Sample Type
  • Blood
  • Urine

• Setting
  • Laboratory Setting
  • Point of Care Setting

• Application
  • Diagnosis Use
  • Research & Development

• End-user
  • Academic Research Centers
  • Diagnostic Laboratories
  • Hospitals & Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cystatin C Assay Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cystatin C Assay Market?

3. What are the technology trends and regulatory frameworks in the Cystatin C Assay Market?

4. What is the market share of the leading vendors in the Cystatin C Assay Market?

5. Which modes and strategic moves are suitable for entering the Cystatin C Assay Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of kidney diseases and growing geriatric population
    • 5.1.1.2. Progressive investments in healthcare infrastructures for renal disorders
  • 5.1.2. Restraints
    • 5.1.2.1. High development costs of cystatin C assays and incidences of product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in cystatin C assay testing
    • 5.1.3.2. Emerging research for adoption of cystatin C assays as alternative to creatinine-based tests
  • 5.1.4. Challenges
    • 5.1.4.1. Dearth of skilled lab professionals and technical challenges associated with cystatin C assay
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Consumer preference cystatin C analyzer for diagnosis and monitoring conditions
  • 5.2.2. Method: Expanding usage of enzyme-linked immunosorbent assay (ELISA) for cystatin C assays
  • 5.2.3. Setting: Expanding usage of point-of-care setting for cystatin C assays
  • 5.2.4. Sample Type: Significant role urine sample for cystatin C assay for measuring the amount of creatinine in a sample
  • 5.2.5. Application: Increasing application of cystatin C assays for diagnosis of renal function
  • 5.2.6. End-user: Expanding usage of cystatin C assays in academic research centers for studying biomarkers
• 5.3. Market Trend Analysis
  • 5.3.1. Well-established healthcare infrastructure coupled with emphasis on commercializing Cystatin C Assay solutions in the Americas
  • 5.3.2. Supportive government programs to reduce the burden of renal disorders in the Asia-Pacific region
  • 5.3.3. Growing focus on developing and expanding novel cystatin C assays products in the EMEA region
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Cystatin C Assay Market, by Product

• 6.1. Introduction
• 6.2. Analyzer
• 6.3. Kits
• 6.4. Reagents

7. Cystatin C Assay Market, by Method

• 7.1. Introduction
• 7.2. Chemiluminescence Immunoassay
• 7.3. Enzyme linked Immunosorbent Assay
• 7.4. Immunofluorescence Assay
• 7.5. Particle-enhanced Nephelometric Immunoassay
• 7.6. Particle-enhanced Turbidimetric Immunoassay

8. Cystatin C Assay Market, by Sample Type

• 8.1. Introduction
• 8.2. Blood
• 8.3. Urine

9. Cystatin C Assay Market, by Setting

• 9.1. Introduction
• 9.2. Laboratory Setting
• 9.3. Point of Care Setting

10. Cystatin C Assay Market, by Application

• 10.1. Introduction
• 10.2. Diagnosis Use
• 10.3. Research & Development

11. Cystatin C Assay Market, by End-user

• 11.1. Introduction
• 11.2. Academic Research Centers
• 11.3. Diagnostic Laboratories
• 11.4. Hospitals & Clinics

12. Americas Cystatin C Assay Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Cystatin C Assay Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Cystatin C Assay Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Jana Care Raises USD 6 Million for Commercialisation of Self-Administered Blood Tests
  • 15.3.2. LordsMed Announces the Launch of its First Pathology Centre in Maharashtra
  • 15.3.3. Renalyse Closes a EUR 1 Million Funding Round with the Participation of GENESIS Ventures
  • 15.3.4. Renalytix Selects EVERSANA to Expand Commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
  • 15.3.5. New European Cystatin C Equation for eGFR May Be More Accurate
  • 15.3.6. Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
  • 15.3.7. Gentian Diagnostics ASA Signs Distribution Agreement for Cystatin C
  • 15.3.8. Bloom Diagnostics Launches New Kidney Test

16. Competitive Portfolio

• 16.1. Key Company Profiles
• 16.2. Key Product Portfolio